Latest Breaking News On - Roland hecht - Page 1 : comparemela.com

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements Selexis SA and Generium JSC today announced that Genolar, Generium's biosimilar of omalizumab, is now commercially

Arkhangel skaya oblastKostenloser wertpapierhandelSelexis generiumRobert meisterDaniil talyanskiyVsevolod letskoRoland hechtMike beyerSelexis company inquiriesSam brown incCorporate communicationsLife sciencesBusiness developmentThird biosimilarMarket underGenerium commercial license